GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kala Bio Inc (NAS:KALA) » Definitions » 9-Day RSI

Kala Bio (Kala Bio) 9-Day RSI

: 14.50 (As of Today)
View and export this data going back to 2017. Start your Free Trial

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.

As of today (2024-04-19), Kala Bio's 9-Day RSI is 14.50.

The industry rank for Kala Bio's 9-Day RSI or its related term are showing as below:

KALA's 9-Day RSI is ranked better than
97.78% of 1575 companies
in the Biotechnology industry
Industry Median: 39.06 vs KALA: 14.50

Competitive Comparison

For the Biotechnology subindustry, Kala Bio's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kala Bio 9-Day RSI Distribution

For the Biotechnology industry and Healthcare sector, Kala Bio's 9-Day RSI distribution charts can be found below:

* The bar in red indicates where Kala Bio's 9-Day RSI falls into.



Kala Bio  (NAS:KALA) 9-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kala Bio  (NAS:KALA) 9-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.


Kala Bio 9-Day RSI Related Terms

Thank you for viewing the detailed overview of Kala Bio's 9-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Kala Bio (Kala Bio) Business Description

Traded in Other Exchanges
Address
1167 Massachusetts Avenue, Arlington, MA, USA, 02476
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing innovative therapies for rare and severe eye diseases. KALA's lead product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
Executives
Todd Bazemore officer: Chief Operating Officer C/O DYAX CORP., 55 NETWORK DRIVE, BURLINGTON MA 01803
Romulus K Brazzell officer: Chief Medical Officer C/O INSPIRE PHARMACEUTICALS, INC., 4222 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
Eric Trachtenberg officer: See Remarks 1414 RALEIGH ROAD, SUITE 400, CHAPEL HILL NC 27517
Darius Kharabi officer: CHIEF BUSINESS OFFICER C/O KALA PHARMACEUTICALS, INC., 490 ARSENAL WAY, SUITE 120, WATERTOWN MA 02472
Mark T Iwicki director, officer: Chief Executive Officer 84 WATERFORD DRIVE, MARLBOROUGH MA 01752
Mary Reumuth officer: Chief Financial Officer 100 BEAVER STREET, SUITE 201, WALTHAM MA 02453
Marjan Farid director C/O KALA PHARMACEUTICALS, INC., 1167 MASSACHUSETTS AVENUE, ARLINGTON MA 02476
Ra Capital Healthcare Fund Lp director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Mark S. Blumenkranz director C/O 1LIFE HEALTHCARE, INC., ONE EMBARCADERO CENTER, SUITE 1900, SAN FRANCISCO CA 94111
Hongming Chen officer: Chief Scientific Officer 100 BEAVER STREET, SUITE 201, WALTHAM MA 02453
C. Daniel Myers director 6120 WINDWARD PARKWAY, SUITE 290, ALPHARETTA GA 30005
Gregory Grunberg director 100 BEAVER STREET, WALTHAM MA 02453
Rajeev M. Shah director 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Peter Kolchinsky director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Management, L.p. director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116